PolyNovo Limited (ASX:PNV)

Australia flag Australia · Delayed Price · Currency is AUD
0.8750
0.00 (0.00%)
Aug 7, 2026, 4:10 PM AEST
Market Cap604.49M -26.5%
Revenue (ttm)139.49M +20.7%
Net Income9.88M +67.3%
EPS0.01 +67.6%
Shares Out 690.84M
PE Ratio62.18
Forward PE45.57
Dividendn/a
Ex-Dividend Daten/a
Volume1,355,927
Open0.8750
Previous Close0.8750
Day's Range0.8650 - 0.8900
52-Week Range0.8100 - 1.6650
Beta1.35
AnalystsBuy
Price Target1.46 (+66.86%)
Earnings DateAug 26, 2026

About PolyNovo

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to tre... [Read more]

Sector Healthcare
Founded 1998
Employees 301
Stock Exchange Australian Securities Exchange
Ticker Symbol PNV
Full Company Profile

Financial Performance

In fiscal year 2025, PolyNovo's revenue was 128.70 million, an increase of 24.67% compared to the previous year's 103.23 million. Earnings were 13.21 million, an increase of 151.17%.

Financial Statements

Analyst Summary

According to 8 analysts, the average rating for PNV stock is "Buy." The 12-month stock price target is $1.46, which is an increase of 66.86% from the latest price.

Price Target
$1.46
(66.86% upside)
Analyst Consensus: Buy
Stock Forecasts

News

PolyNovo Earnings release: Trading update

PolyNovo released its earnings on July 22, 2026, summarizing the period's financial results.

15 days ago - Filings

PolyNovo Earnings Call Transcript: H1 2026

Group sales rose 26% to AUD 68.2 million, led by strong U.S. and international growth, with Adjusted EBITDA up 82%. Manufacturing capacity expanded, clinical evidence base strengthened, and new markets targeted for further acceleration.

6 months ago - Transcripts

PolyNovo Quarterly report: H1 2026

PolyNovo has published its H1 2026 quarterly earnings report on February 19, 2026.

6 months ago - Filings

PolyNovo Slides: H1 2026

PolyNovo has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 19, 2026.

6 months ago - Filings

PolyNovo Slides: Investor Presentation

PolyNovo has posted slides in relation to its latest quarterly earnings report, which was published on November 17, 2025.

9 months ago - Filings

PolyNovo Transcript: AGM 2025

The meeting highlighted strong financial growth, global expansion, and robust product innovation, while addressing governance reforms and executive turnover. Shareholders raised concerns about transparency and board changes, with new leadership and strategic initiatives positioned for future growth.

10 months ago - Transcripts

PolyNovo Earnings Call Transcript: H2 2025

Record sales and profit growth were driven by strong U.S. and international demand, new product launches, and operational leverage. Cash flow and margins improved, with continued expansion into new markets and indications expected to sustain momentum.

1 year ago - Transcripts

PolyNovo Annual report: H2 2025

PolyNovo has published its H2 2025 annual report on August 25, 2025.

1 year ago - Filings

PolyNovo Slides: H2 2025

PolyNovo has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 25, 2025.

1 year ago - Filings